New pill for weight and diabetes gets first human dosing test
NCT ID NCT06506175
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests how the body processes HRS9531 tablets under different dosing conditions. It involves 100 healthy adults aged 18-55 with a BMI between 23 and 35. The goal is to measure drug levels and safety, not yet to treat weight or diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS9531 tablets
- What this could lead to
- If successful, this could help determine the best way to take HRS9531 for managing weight and type 2 diabetes.
- What could go wrong
- This is an early Phase 1 study in healthy people, so it won't show if the drug actually works for weight or diabetes. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The affiliated hospital of Qingdao University
Qingdao, Shandong, 266000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a daily probiotic boost metabolic health and body confidence?
- Blood test could predict who faces rapid kidney decline in diabetes
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes